- Home
- RENB vs SEER Comparison
RENB vs SEER Comparison
Compare RENB & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENB
- SEER
- Stock Information
- Founded
- RENB 2011
- SEER 2017
- Country
- RENB United States
- SEER United States
- Employees
- RENB N/A
- SEER N/A
- Industry
- RENB Biotechnology: Pharmaceutical Preparations
- SEER Medicinal Chemicals and Botanical Products
- Sector
- RENB Health Care
- SEER Health Care
- Exchange
- RENB Nasdaq
- SEER Nasdaq
- Market Cap
- RENB 61.0M
- SEER 117.2M
- IPO Year
- RENB N/A
- SEER 2020
- Fundamental
- Price
- RENB $0.32
- SEER $1.87
- Analyst Decision
- RENB
- SEER Hold
- Analyst Count
- RENB 0
- SEER 1
- Target Price
- RENB N/A
- SEER $3.00
- AVG Volume (30 Days)
- RENB 736.8K
- SEER 184.6K
- Earning Date
- RENB 05-19-2025
- SEER 05-13-2025
- Dividend Yield
- RENB N/A
- SEER N/A
- EPS Growth
- RENB N/A
- SEER N/A
- EPS
- RENB N/A
- SEER N/A
- Revenue
- RENB N/A
- SEER $14,170,000.00
- Revenue This Year
- RENB N/A
- SEER $23.54
- Revenue Next Year
- RENB N/A
- SEER $42.98
- P/E Ratio
- RENB N/A
- SEER N/A
- Revenue Growth
- RENB N/A
- SEER N/A
- 52 Week Low
- RENB $0.29
- SEER $1.56
- 52 Week High
- RENB $2.34
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- RENB 36.60
- SEER 45.89
- Support Level
- RENB $0.29
- SEER $1.85
- Resistance Level
- RENB $0.35
- SEER $2.09
- Average True Range (ATR)
- RENB 0.05
- SEER 0.10
- MACD
- RENB 0.01
- SEER -0.01
- Stochastic Oscillator
- RENB 16.20
- SEER 17.24
About RENB Renovaro Biosciences Inc.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.